Literature DB >> 17925536

Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.

S Lilly Zheng1, Jielin Sun, Yu Cheng, Ge Li, Fang-Chi Hsu, Yi Zhu, Bao-Li Chang, Wennuan Liu, Jin Woo Kim, Aubrey R Turner, Marta Gielzak, Guifang Yan, Sarah D Isaacs, Kathleen E Wiley, Jurga Sauvageot, Huann-Sheng Chen, Robin Gurganus, Leslie A Mangold, Bruce J Trock, Henrik Gronberg, David Duggan, John D Carpten, Alan W Partin, Patrick C Walsh, Jianfeng Xu, William B Isaacs.   

Abstract

BACKGROUND: Recent studies have provided evidence of associations between genetic markers at human chromosome 8q24 and an increased risk of prostate cancer. We examined whether multiple independent risk variants exist in this region and whether the strength of observed associations differs as a function of disease aggressiveness.
METHODS: We evaluated associations between 18 single-nucleotide polymorphisms (SNPs) in a 1-Mb interval at 8q24 and the risk of prostate cancer among 1563 case patients (1017 of whom had high-grade [Gleason score > or = 7] and/or non-organ-confined disease) and 576 control subjects of European American ancestry. Differences in genotype frequencies between case and control subjects were compared using logistic regression analysis, with adjustment for age, and the Wald chi-square test. All statistical tests were two-sided.
RESULTS: We identified multiple SNPs in a 50-kb region (referred to as locus 1) that are in linkage disequilibrium with a previously reported risk-associated SNP at 8q24, rs1447295, but were more strongly associated with prostate cancer risk in our study population. We also identified a novel susceptibility SNP, rs6983267, at a second locus (locus 2) that is approximately 70 kb centromeric of rs1447295 and in linkage equilibrium with, and independent of, locus 1. Risk alleles at locus 2 were common in our study population (minor allele frequency approximately 50%, 25% homozygous for risk-associated allele). Analysis of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer association study database alone and in combination with our data provided further evidence for this second prostate cancer risk locus; in the combined analysis, the allele frequencies for rs6983267 differed statistically significantly between case patients and control subjects (P = 1.61 x 10(-9)). We also identified a third locus at 8q24, approximately 400 kb centromeric to locus 2, that was statistically significantly associated with prostate cancer risk in a combined analysis of our data and CGEMS study data (P = 6.8 x 10(-4)). A joint analysis of loci 1 and 2 indicated that 35% of the control subjects carried risk genotypes at one or both these loci; compared with men with the non-risk genotype at both loci, men with risk genotypes at both loci had an odds ratio of prostate cancer of 2.68 (95% confidence interval [CI] = 1.62 to 4.43) and men with risk genotypes at either locus had an odds ratio of prostate cancer of 1.70 (95% CI = 1.39 to 2.07).
CONCLUSIONS: Three loci at 8q24 are independent genetic risk factors for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925536     DOI: 10.1093/jnci/djm169

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  77 in total

1.  Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Authors:  Barry B McGuire; Brian T Helfand; Shilajit Kundu; Qiaoyan Hu; Jessica A Banks; Phillip Cooper; William J Catalona
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Authors:  Sarah M Troutman; Tristan M Sissung; Cheryl D Cropp; David J Venzon; Shawn D Spencer; Bamidele A Adesunloye; Xuan Huang; Fatima H Karzai; Douglas K Price; William D Figg
Journal:  Oncologist       Date:  2012-03-01

3.  Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history.

Authors:  Fang-Chi Hsu; Jielin Sun; Yi Zhu; Seong-Tae Kim; Tao Jin; Zheng Zhang; Fredrik Wiklund; A Karim Kader; S Lilly Zheng; William Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

Review 4.  Identification of new genetic risk factors for prostate cancer.

Authors:  Michelle Guy; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angela Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jameson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton; Rosalind A Eeles
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

Review 5.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

6.  Multiple loci on 8q24 associated with prostate cancer susceptibility.

Authors:  Ali Amin Al Olama; Zsofia Kote-Jarai; Graham G Giles; Michelle Guy; Jonathan Morrison; Gianluca Severi; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Sameer Jhavar; Ed Saunders; John L Hopper; Melissa C Southey; Kenneth R Muir; Dallas R English; David P Dearnaley; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Rosemary A Wilkinson; Emma Sawyer; Artitaya Lophatananon; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin Cooper; Jenny L Donovan; Freddie C Hamdy; David E Neal; Rosalind A Eeles; Douglas F Easton
Journal:  Nat Genet       Date:  2009-09-20       Impact factor: 38.330

7.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

8.  Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.

Authors:  Jianfeng Xu; Siqun Lilly Zheng; Sarah D Isaacs; Kathleen E Wiley; Fredrik Wiklund; Jielin Sun; A Karim Kader; Ge Li; Lina D Purcell; Seong-Tae Kim; Fang-Chi Hsu; Pär Stattin; Jonas Hugosson; Jan Adolfsson; Patrick C Walsh; Jeffrey M Trent; David Duggan; John Carpten; Henrik Grönberg; William B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

9.  Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Authors:  Eric J Whitman; Mark Pomerantz; Yongmei Chen; Michael M Chamberlin; Bungo Furusato; Chunling Gao; Amina Ali; Lakshmi Ravindranath; Albert Dobi; Isabell A Sesterhenn; Isabell A Sestrehenn; David G McLeod; Shiv Srivastava; Matthew Freedman; Gyorgy Petrovics
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

10.  Genetic variants and family history predict prostate cancer similar to prostate-specific antigen.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Zhengrong Gao; Pär Stattin; Lina D Purcell; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Jan Adolfsson; Jan-Erik Johansson; Aubrey R Turner; Tamara S Adams; Wennuan Liu; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.